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Abstract Cerebral atherosclerosis (AS), small vessel
disease (SVD), and cerebral amyloid angiopathy (CAA)
are the most prevalent arterial disorders in the aged brain.
Pathogenetically, AS and SVD share similar mechanisms:
plasma protein leakage into the vessel wall, accumulation
of lipid-containing macrophages, and fibrosis of the vessel
wall. CAA, on the other hand, is characterized by the
deposition of the amyloid b-protein in the vessel wall.
Despite these differences between CAA, AS and SVD,
apolipoprotein E (apoE) is involved in all three disorders.
Such a pathogenetic link may explain the correlations
between AS, SVD, CAA, and Alzheimer’s disease in the
brains of elderly individuals reported in the literature. In
addition, AS, SVD, and CAA can lead to tissue lesions
such as hemorrhage and infarction. Moreover, intracerebral
SVD leads to plasma protein leakage into the damaged
vessel wall and into the perivascular space resulting in a
blood–brain barrier (BBB) dysfunction. This SVD-related
BBB dysfunction is considered to cause white matter
lesions (WMLs) and lacunar infarcts. In this review, we
demonstrate the relationship between AS, SVD, and CAA
as well as their contribution to the development of vascular
tissue lesions and we emphasize an important role for apoE
in the pathogenesis of vessel disorders and vascular tissue
lesions as well as for BBB dysfunction on WML and
lacunar infarct development.
Keywords Atherosclerosis  Small vessel disease 
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Introduction
The three most important vessel disorders in the elderly
brain are cerebral atherosclerosis (AS), small vessel disease
(SVD), and cerebral amyloid angiopathy (CAA). All three
disorders can lead to infarction and hemorrhage [56, 87,
102]. SVD is also associated with white matter lesions
(WMLs) [48]. Infarction, hemorrhage, and WMLs cause
the destruction of brain tissue and, thereby, frequently
cause neurological symptoms.
This review is aimed at identifying pathogenetic
mechanisms involved in AS, SVD, and CAA that may
explain their correlation with one another and with vascular
lesions, such as hemorrhage, infarction, and WMLs. To
address this aim, we will first summarize the current
knowledge about these vessel disorders. Second, we will
discuss the correlation between these vessel diseases and
the proteins involved in the pathogenesis of all three dis-
orders. Third, we will summarize the current concepts
about the involvement of apolipoprotein E (apoE) in these
vessel disorders, and discuss potential pathogenetic
mechanisms that may represent a link among them. Then,
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the relationship between the vessel disorders and vascular
brain lesions will be reported and pathogenetic mecha-
nisms will be discussed.
Pathology of major vessel disorders in the aging brain
Atherosclerosis
Atherosclerosis is a degenerative vessel disorder that fre-
quently affects large- to medium-sized arteries. In the brain,
the vessels of the circle of Willis are often involved [5, 66].
The occurrence and the severity of AS in the circle of Willis
increase with age (Table 1). AS changes in small arteries
overlap with those found in SVD. Atherosclerotic plaques
are prone to rupture with subsequent thrombosis [119, 120].
The thrombus resulting from plaque rupture can either lead
to vessel occlusion or it can embolize and occlude a smaller
artery [73]. Embolism is most frequently originated from the
extracerebral parts of the vertebral artery and the common
and internal carotid arteries [73]. Atherosclerotic aneurysm
is a consequence of cerebral vessel wall destruction, rarely
leading to subsequent rupture and hemorrhage [56].
Intima thickening and accumulation of blood-derived
lipids in the intima initiate the development of AS [66, 121].
Further intima proliferation, splitting of the lamina elastica
interna and the accumulation of cholesterol-laden macro-
phages lead to the generation of atherosclerotic plaques
[119–121] (Fig. 1a, b), which is accompanied by further
destruction of the vessel wall and the accumulation of
T-lymphocytes and macrophages [42, 119–121]. In later
stages, AS plaques exhibit a necrotic core, cholesterol clefts
and calcifications [119]. AS plaque rupture is associated with
(1) inflammation, including the secretion of cytokines [e.g.
interleukin (IL)-1a, IL-12, IL-18], (2) collagen-degrading
enzymes, such as matrix-metalloproteinases (e.g. MMP-1,
MMP-9) and the neutrophil elastase, which are involved in
the degradation of the vessel wall [20, 21, 23, 71, 72], (3)
anti-oxidative stress response as indicated by the presence of
glutathione-S-transferase omega [65], and (4) endothelial/
intimal alteration as indicated by the occurrence of plasma
proteins [e.g. a2-macroglobulin (A2M; Fig. 1), neutrophil
elastase] in the AS plaque [70, 117]. Arterial hypertension is
a well-known risk factor for AS [76] and may foster plasma
protein leakage into the vessel wall. Other risk factors are
increased homocysteine plasma levels found in AS patients
[148] and the 677C-T mutation in the MTHFR gene
(methylenetetrahydrofolate reductase—an enzyme that is
involved in the remethylation of homocysteine, the mutation
results in increased plasma homocysteine levels) [32].
ApoE and its receptors are critically involved in the
pathogenesis of AS. ApoE-knockout mice and low-den-
sity lipoprotein (LDL) receptor knockout mice develop
AS [8, 156]. Dysfunctional uptake of LDLs may, thereby,
lead to the accumulation of oxidized LDLs in the ath-
erosclerotic vessel wall [9]. Thus, oxidized LDLs may be
candidates to trigger the development of atherosclerotic
plaques. ApoE and LDL receptors [e.g. LDLR and A2M
receptor/LDL receptor-related protein (LRP = CD91)]
were found in AS plaques (Fig. 1c) [8, 43]. The apoE e4
allele is controversially discussed as a possible genetic
risk factor for AS [64, 75, 116]. The second ligand of
LRP, the plasma protein A2M, also accumulates within
AS plaques (Fig. 1d) [117] and an association of its
deletion/insertion polymorphism with the expansion of AS
plaques within the circle of Willis has been reported [70].
The accumulation of A2M within the AS plaque did not
correlate with the type of the AS lesions [71] suggesting
that plasma protein influx including A2M may play a role
in the initiation of AS plaques but not for plaque rupture.
In summary, apoE, LDL receptors and A2M are involved
in the pathogenesis of AS. Leakage of plasma apoE and
A2M possibly contributes to the development of AS
plaques.
Table 1 Distribution of frequencies of autopsy cases with a given extent of atherosclerosis (AS) within the arteries of the circle of Willis (CaW)
among different age groups
Extent of AS Frequency of cases/% in the age group
60–70 years 71–80 years 81 years and older
No AS 20.69 3.57 4.00
1–25% of CaW vessels with AS 17.24 7.14 12.00
26–50% of CaW vessels with AS 20.69 32.14 8.00
51–75% of CaW vessels with AS 24.14 35.71 40.00
76–100% of CaW vessels with AS 17.24 21.43 36.00
The table presents the percentage of cases without AS and with AS in a given extent in the age groups 60–70, 71–80, and 81 years and older. This
observation is based on the data obtained from 82 non-selected autopsy cases. The circle of Willis was observed macroscopically for the presence
or absence of the 11 arteries of the circle of Willis as previously described [70]. The extent of AS was calculated as: number of AS-affected
vessels 9 100/number of investigated vessels of the circle of Willis [70]. The cases analyzed here were already included in other studies under
other aspects [65, 70]
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Small vessel disease
Small vessel disease encompasses degenerative alterations
in the vessel wall of the small arteries and arterioles that
are assumed to be pathogenetically linked [51, 67, 142].
SVD includes changes also described as small vessel
arteriosclerosis/atherosclerosis, arteriolosclerosis, and lip-
ohyalinosis [51, 67, 142]. These three subforms of SVD
and how they are pathogenetically linked to one another
will be discussed hereunder. CAA is not included in this
group basically because of differences in the pathogenesis
and the location of affected vessels.
Small vessel arteriosclerosis/atherosclerosis constitutes
AS in small intracerebral and leptomeningeal arteries
(200–800 lm in diameter). The vessels show endothelial
proliferation, splitting of the lamina elastica interna
(Fig. 2a), small plaque-like accumulations of plasma pro-
teins, lymphocytes and macrophages (microatheroma) [31,
67]. The pathogenesis is similar to that of AS including the
role of apoE leakage and the mechanisms responsible for
thrombosis and hemorrhage development [67]. Smaller
arteries (40–300 lm) exhibit asymmetric areas of fibrosis/
hyalinosis associated with foam cells and leakage of
plasma proteins such as apoE, A2M, and immunoglobulin
G (IgG) (Fig. 2b–f) termed lipohyalinosis. The initial
lesion is a fibrinoid necrosis of the vessel wall in the
absence of inflammation [67]. High arterial pressure and
blood–brain barrier (BBB) breakdown are implicated
in plasma protein leakage and fibrinoid necrosis in this
disease [68, 91, 92]. Lipohyalinosis is different from con-
centric hyaline thickening of small arteries (40–150 lm in
diameter) leading to a concentric stenosis of the vessel
lumen (Fig. 2g) [67] termed arteriolosclerosis. Due to the
high blood pressure, plasma proteins, such as albumin,
A2M and apoE, leak into the vessel wall and into the
perivascular brain parenchyma [1, 139] (Fig. 2h–i). These
changes are usually seen in white matter arteries [84, 140,
151].
SVD is first seen in the arteries of the basal ganglia,
mainly in the putamen and the globus pallidus, which
exhibit small vessel AS and lipohyalinosis. Secondly, small
white matter arteries become affected by arteriolosclerosis
or lipohyalinosis. Leptomeningeal arteries of the hemi-
spheres and the cerebellum develop small vessel AS in
parallel. Brain stem arteries, including those located
between the pontine nuclei, usually develop lipohyalinosis
or arteriolosclerosis only in the end stage of SVD [129].
Cortical vessels are usually free of SVD [129]. Enlarged
Fig. 1 a, b The left internal
carotid artery of a 79-year-old
man exhibits severe
atherosclerotic changes (Type 5
according to Stary [119]). There
is a thinning of the lamina
media, proliferation and lipid
accumulation in the intima
including cholesterol clefts
(arrows). The necrotic core is
covered by a fibromuscular
tissue layer (arrowheads)
indicative for Stary Type 5
lesions. b Corresponds to a high
magnification view of the boxed
area in (a). ApoE (c) and A2M
(d) occur in the plaque core of
an AS plaque. Staining in (a, b)
Elastica van Gieson (EVG),
c anti-apoE [Covance (Dedham,
USA), D6E10, 1/500, formic
acid and microwave
pretreatment], d anti-A2M
[BioMac (Germany, Leipzig),
polyclonal rabbit, 1/5,000]. The
calibration bar in (b)
corresponds to: a 400 lm,
b 90 lm, c, d 70 lm
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perivascular spaces are often associated with SVD-affected
vessels. As such, all subforms of SVD contribute to this
hierarchical expansion of SVD changes throughout the
brain and seem to be pathogenetically linked.
Arterial hypertension and diabetes mellitus are risk
factors for SVD [69]. However, this association is lacking
in a significant number of cases [69]. Plasma protein
leakage into the vessel wall including apoE and A2M is a
common feature in all three subforms of SVD (Fig. 2c–e,
h, j). Genetically, an association between SVD and the
apoE e4 allele has been reported [154].
Cerebral amyloid angiopathy
Deposits of amyloid b-protein (Ab) in the cerebral and
leptomeningeal vessel walls are characteristic of CAA in
Fig. 2 Small vessel disease-related changes. a A leptomeningeal
artery shows intima proliferation and a splitting of the internal elastic
lamina (arrow). These changes are related to small vessel arterio-
sclerosis/atherosclerosis. b A white matter artery exhibits fibrosis,
lipohyalinosis of the vessel wall, and fibrinoid necrosis (arrow).
Lipohyalinosis affected vessels exhibit the plasma proteins apoE (c),
A2M (d), and IgG (e) within the vessel wall (arrows in c–e) indicating
the leakage of plasma proteins into the vessel wall and into the
perivascular space (asterisk in e). f Macrophages within the lipohyali-
notic lesions and perivascular astrocytes strongly exhibit the A2M and
apoE receptor LRP (CD91) (arrows) indicating that these cells are
capable of taking up A2M and apoE. g Arteriolosclerosis of a white
matter artery shows severe hyalinization (arrow) of the vessel wall. h–j
ApoE and A2M were observed within the vessel wall of arterioloscle-
rotic vessels (arrows in h, i). Within the enlarged perivascular spaces
high numbers of apoE (h), A2M (i), and LRP-positive cells (arrow in j)
were observed indicating that these perivascular cells accumulate apoE
and A2M due to an insufficient perivascular drainage. These perivas-
cular macrophages are often Prussian blue negative and do not
necessarily represent hemorrhagic residues [129]. Stainings in a–j as
indicated. Anti-apoE and anti-A2M staining was performed as
indicated in Fig. 1. For anti-IgG and anti-LRP immunohistochemistry
the following antibodies were used [anti-IgG: polyclonal goat; Biome-
da, Foster City, CA; 1/100; microwave pretreatment; anti-LRP (anti-
CD91): a2-M-R-II2C7; BioMac, Leipzig, Germany; 1/150; microwave
and protease pretreatment]. The calibration bar in i corresponds to:
a 300 lm, b 80 lm, c 40 lm, d, j 35 lm, e, f 60 lm, g 20 lm, h 16 lm,
i 50 lm. a and b are reproduced from Thal et al. 2003 [129] with kind
permission
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both sporadic and Ab-related familiar forms [34, 55, 108].
Ab deposits occur in arteries, veins and capillaries [141]
(Fig. 3a, b). Ab40 is more predominant in vascular Ab
deposits than in parenchymal ones [45, 110]. In the
sporadic form of CAA, vascular Ab deposition is strongly
associated with AD-related pathology and around 80–
100% of all AD patients have CAA [3, 4, 51, 55, 108,
126, 129, 132, 141]. Morphologically, two types of CAA
can be distinguished: CAA with capillary involvement
(CAA-type 1) and CAA lacking capillary Ab deposition
(CAA-type 2) [130]. Capillary CAA is more common in
AD patients [4, 132] and it can induce capillary occlusions
resulting in disturbances of cerebral blood flow [128].
The severity of CAA is related to the degree of vessel
wall destruction [144]. Intracerebral hemorrhage, cerebral
infarction [14, 79, 132, 141], and CAA-related angiitis
[62, 78, 107] are complications of CAA (Fig. 3c).
CAA begins in cortical and leptomeningeal vessels of
neocortical areas and then, expands into vessels of allo-
cortical areas and the cerebellum. In single cases, even
white matter arteries and vessels of the basal ganglia, the
diencephalon, and/or the brain stem exhibit CAA [129,
132]. This hierarchical pattern resembles the one described
for Ab plaques [2, 131, 134].
Physiologically, brain-derived Ab is drained along the
perivascular space [15, 147] and the vascular basement
membranes [16, 146]. Alterations of this clearance path-
way may result in the deposition of Ab near the basement
membrane [146]. In addition, smooth muscle cell-derived
Ab is potentially capable of contributing to the deposition
of Ab in the vessel wall [85, 86]. ApoE plays an important
role in the pathogenesis of CAA. It is found in vascular Ab
deposits [93] and it is physiologically drained along the
perivascular space co-occurring with Ab [133, 139]. ApoE
binds Ab [123]. Alterations of the perivascular drainage of
Ab and apoE likely lead to CAA [133, 146, 147]. CAA,
especially capillary CAA, is associated with the apoE e4
allele [37, 100, 103, 126, 130, 132]. This finding points to
an important role of apoE for the development of CAA
because apoE4 is less effective in the receptor-mediated
clearance of Ab when compared to apoE3 [19]. This
property of apoE4 presumably results in capillary Ab
deposition in apoE e4 carriers as soon as alterations in the
perivascular drainage occur. In addition, the apoE e4-
genotype promotes Ab aggregation in vascular smooth
muscle cell cultures [85]. Finally, CAA-related hemor-
rhage is reported to be associated with the apoE e2 and e4
allele [37, 88, 95, 97].
In familial cases, other amyloidogenic proteins can also
aggregate in the cerebral blood vessels and cause other
forms of CAA, i.e., ABri, ADan, transthyrretin, gelsolin,
cystatin D, and prion protein [108]. Unlike Ab-related
CAA, these forms of CAA are usually not restricted to the
cerebral and leptomeningeal vessels [108].
Relationship between SVD subforms, AS, and CAA
Although AS, SVD, and CAA are distinct disease entities,
they correlate with one another as well as with AD except
for AS, which did not correlate with CAA [5, 13, 109, 129].
In our own sample, we confirmed the correlation between
AS and SVD, SVD and CAA, SVD and AD, and CAA
and AD whereas there was no significant correlation
between AS and CAA, and AS and AD (Table 2). In the
Fig. 3 Cerebral amyloid angiopathy (CAA). a Ab deposition in the
vessel wall of leptomeningeal arteries (A) and veins (V) as well as in
cortical arteries (arrows). b Capillary CAA is characterized by Ab
deposits at the basement membrane of cortical capillaries (arrows).
c Severe CAA in a case of CAA-related hemorrhage. The CAA-
affected artery exhibits multiple aneurysmal dilations of the vessel
wall as indicated by arrows. Ab deposits are stained in red
(permanent red; DAKO, Glostrup, Denmark) with an antibody
against Ab17–24 (4G8, Covance, Dedham, USA, 1/5,000, pretreatment
with formic acid). The same antibody was also used in figures
a and b but 3,3-diaminobencidine–HCl was used as chromogen. The
calibration bar in b corresponds to: a 85 lm, b, c 20 lm
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light of these correlations, it is tempting to speculate that
AS, SVD, and CAA share common or linked pathogenetic
mechanisms.
SVD and AS exhibit similar morphological alterations.
For example, atherosclerotic lesions in small arteries are
defined either as AS or as SVD (subform: small vessel
arteriosclerosis/atherosclerosis). Partly, this overlap is
explained by the similarities of the pathogenetic mecha-
nism of AS in large- and medium-sized vessels as well as
in small vessels [67], such as plasma protein leakage into
the vessel wall. On the other hand, there are morphological
differences that justify the distinction between AS and the
SVD subform small vessel arteriosclerosis/atherosclerosis:
AS plaques in large- and medium-sized vessels often
contain cholesterol clefts and calcifications, which are
usually not seen in small vessel arteriosclerosis/athero-
sclerosis.
SVD itself is subclassified into small vessel arterio-
sclerosis/atherosclerosis, arteriolosclerosis, and lipohyalinosis/
fibrinoid necrosis. Despite morphological differences,
plasma protein leakage into the vessel wall and/or into the
perivascular space are common features of all three sub-
forms (Figs. 2, 4a). The hierarchical expansion of SVD,
encompassing all of its subforms, throughout the brain, as
described in detail in ‘‘Small vessel disease’’, also argues in
favor of a common disease entity with different presenta-
tions in larger and smaller vessels rather than three
different vessel disorders.
A pathogenetic link between AS and SVD on the one
hand and CAA on the other is less obvious. However, apoE
occurs in the SVD- and AS-related vessel wall lesions and
in association with CAA-related Ab deposits. Moreover,
the apoE e4 allele is a risk factor for CAA [100, 115, 126],
SVD [154], and is discussed as a risk factor for AS [64, 75,
116]. The absence of apoE in apoE-knockout mice results
in AS and hypercholesterolemia [156]. These points indi-
cate that apoE is a common player in the pathogenesis of
all three vessel disorder and may represent a pathogenetic
link.
The role of apoE in vessel pathology of the aging brain
Apolipoprotein E appears to be a common player in the
pathogenesis of AS, SVD, and CAA. It is a plasma protein
produced by hepatocytes and macrophages [77] and it
functions as a transporter for cholesterol and other lipids
[77]. In the brain, apoE is produced by astrocytes [10, 77].
Under physiological conditions, an intact BBB prevents the
influx of plasma apoE into the brain [22, 27]. Brain-apoE is
drained along perivascular channels and vascular basement
membranes [133]. It can bind cholesterol, lipids, and pro-
teins such as Ab [77, 123], which are cleared together with
apoE [6, 106], suggesting that apoE may have a transporter
function not only for cholesterol and lipids but also for
proteins such as Ab.
In AS- and SVD-affected vessels, plasma proteins
including apoE leak into the vessel wall and accumulate in
the respective lesion [1, 18, 91, 92, 139, 150] (Figs. 1, 2,
4). Plasma proteins also leak into the perivascular space of
vessels affected by SVD indicating an alteration of the pre-
capillary segment of the BBB [127, 139]. Thus, SVD
presumably impairs perivascular clearance, including that
of Ab and apoE, by several mechanisms: (1) SVD-induced
fibrosis of the vessel wall may decrease the capacity for
drainage along the basement membranes [146], (2) the
increasing stiffness of the SVD-affected arteries leads to a
less effective outward transport of the perivascular fluid
due to a cessation of the pulsations [146, 147], and (3) the
SVD-induced leakage of plasma proteins including apoE
into the vessel wall and the perivascular space competes for
perivascular drainage with the extracellular fluid of the
brain [127, 136, 137, 139] (Fig. 4). Therefore, SVD pre-
sumably contributes to the accumulation of Ab in the brain
leading to CAA and Alzheimer’s disease-related Ab plaque
deposition. This hypothesis is supported by the association
between SVD, CAA, and Ab plaque deposition [13, 129]
(Table 2) and by the increase of plasma Ab1–40 in patients
with SVD [35]. Since SVD and CAA are both localized in
intracerebral small arteries and arterioles, which have a
perivascular space, and since both disorders develop apoE-
containing lesions [93, 139] and are associated with the
apoE e4 allele as a genetic risk factor, it is tempting to
assume that apoE represents a pathogenetic link between
SVD and CAA. The hypothesis that apoE contributes
to vessel wall destruction is further supported by the
Table 2 Correlations between extent of cerebral atherosclerosis
(AS), small vessel disease (SVD), cerebral amyloid angiopathy
(CAA), and Alzheimer’s disease (AD)
Correlation between r p n
AS–SVD 0.475 0.003 36
AS–CAA -0.109 0.488 43
AS–AD 0.15 0.175 83
SVD–CAA 0.252 0.025 79
SVD–AD 0.177 0.022 166
CAA–AD 0.575 0.001 87
The extent of AS was obtained as described in the legend of Table 1.
The extent of SVD and CAA was measured by the stage of SVD and
CAA distribution throughout the entire brain [129]. AD was diag-
nosed in the event that the pathology of the demented cases showed a
moderate or high likelihood for AD according to the NIA-Reagan
criteria [135]. Non-AD controls were all cases that did not match the
NIA-Reagan criteria and did not develop dementia
r Spearman rho correlation coefficient, p probability, n number of
cases analyzed
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association of the apoE e2 and e4 alleles with CAA-related
hemorrhages [37, 88, 95, 97].
One argument against the hypothesis that SVD-related
BBB alterations contribute to the development of CAA and
parenchymal Ab deposition is the lacking increase of apoE
in the brain [139]. However, in the event that Ab accu-
mulates in the brain, e.g. in AD cases, apoE clearance
switches from perivascular drainage to enzymatic cleavage
as indicated by the predominance of C-terminal truncated
apoE over full-length apoE [139]. Hence, the absence of an
apoE increase in the brain of AD patients or of patients
with perivascular drainage deficits does not argue against
the hypothesis that altered perivascular drainage of extra-
cellular fluid leads to a congestion of extracellular fluid and
proteins in the brain. Moreover, the increase of 27-
hydroxycholesterol levels in AD brains indicates an influx
of plasma steroids through the BBB [46]. Another argu-
ment against a pathogenetic link between SVD and Ab
accumulation in the brain is that AD-related Ab deposition
in aged individuals first occurs in the cortex [11, 104, 129,
134] whereas SVD affects mainly white matter, leptome-
ningeal and basal ganglia vessels [129]. However, the
cortex is a distal area in relation to the areas with SVD-
affected vessels, and Ab is mainly produced by neurons
located in this distal area [40, 94]. Thus, a proximal
clearance block for peripheral extracellular fluid drainage
containing neuron-derived Ab will lead to a protein accu-
mulation, e.g. of Ab, in distal areas such as the cortex. This
is exactly where parenchymal and vascular Ab deposits
occur first [11, 104, 129, 134]. Therefore, it is tempting to
speculate that the distribution of Ab deposits in aging and
AD brains may represent the result of insufficient clearance
of Ab, rather than an anterograde neuronal expansion as
previously discussed [134]. A strong argument in favor of
this hypothesis is the fact that normal brain transplants into
APP-transgenic mice, which produce a high number of Ab
plaques, also develop Ab plaques in the absence of neu-
ronal connections [89].
Fig. 4 Plasma protein leakage induced by vessel disorders and its
relation to perivascular alterations of the brain parenchyma. a This
schematic representation shows that plasma proteins occur (1) in the
plaque cores of AS plaques, (2) in the vessel wall of lipohyalinotic
vessels as well as in the perivascular space and in macrophages within
the perivascular space, and (3) in the vessel wall of arteriolosclerotic
vessels as well as in accompanying macrophages. CAA, on the other
hand, is characterized by the deposition of proteins of the extracel-
lular fluid of the brain, i.e. Ab [15] and apoE [133]. b Impact of
plasma protein leakage into the brain. Physiologically, extracellular
fluid is drained into the perivascular space and along the vascular
basement membranes [16, 60, 155]. In the event of SVD, there is
plasma protein leakage into the vessel wall and into the perivascular
space [139] resulting in (1) a competition between leaking plasma and
extracellular fluid from the brain for perivascular drainage and (2) the
congestion of extracellular fluid leading to the accumulation and/or
alternative processing of proteins of the extracellular fluid, and 3) the
influx of the peripheral cholesterol metabolite 27-hydroxycholesterol
into the brain [46, 127, 139]. The influx of 27-hydroxycholesterol into
the brain is accompanied by decreased levels of brain derived 24-
hydroxycholesterol indicating a reduction in the cerebral 24-hydrox-
ycholesterol production [46]
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Thus, SVD-related alterations of the BBB may con-
tribute to the development of CAA and possibly of
parenchymal Ab deposition. In general, the results
reviewed here for the fate of Ab and apoE after SVD-
related BBB alteration point to two different effects of
protein retention in the brain (1) accumulation, as docu-
mented for Ab, and (2) degradation as presumed for apoE.
Therefore, it is likely to posit that accumulation or degra-
dation of other proteins also takes place and may be related
with other SVD-associated brain lesions.
Vascular brain lesions and their relationship
to AS, SVD, and CAA
Brain infarction, hemorrhage, and WMLs are the major
brain lesions related to AS, SVD, and CAA. The location
and size of the lesions vary according to the underlying
vessel disorders and the potential risk factors. Here, we will
briefly describe the vascular brain lesions and their asso-
ciation with AS, SVD, and CAA.
Brain infarction
Brain infarction is a circumscribed brain tissue necrosis
resulting from insufficient blood supply [73, 102]. Infarcts
are subdivided by nature into ischemic (anemic) or hemor-
rhagic infarcts. Alternatively, the descriptive classification
distinguishes large infarcts (those involving the supply
territories of major cerebral arteries and veins), lacunar
infarcts (i.e. small vessel infarcts), and microinfarcts.
First, we will describe the relationship between ischemic
and hemorrhagic infarcts to AS, SVD, and CAA regardless
of the size of the infarct. Ischemic infarcts occur when
focal brain perfusion falls below critical levels and no
relevant collateral or remaining blood flow is available.
This type of infarct is seen after thrombosis of large- to
medium-sized arteries with atherosclerotic plaque rupture
with or without subsequent embolism or after occlusion
of SVD- or CAA-affected vessels [14, 73, 141]. Cardiac
embolism also causes ischemic brain infarction [29, 33,
73]. Hemorrhagic infarcts are characterized by blood
influx into the infarct territory. Different mechanisms can
be responsible for hemorrhagic infarcts: (1) embolism due
to AS or cardiac thrombosis [29, 81] with insufficient blood
influx into the infarcted tissue (the mechanism is not clear,
partial lysis of the embolus with resting blood flow, which
is insufficient to save the tissue, is considered), (2) reper-
fusion of an anemic infarct (e.g. following lysis therapy or
resuscitation), (3) collateral blood influx (insufficient to
save the tissue but enough to bleed), (4) infarction in areas
in which the remaining vessels are fragile due to a vessel
disease such as SVD or CAA [41], and (5) venous
obstruction with subsequent congestion and extravasation
of blood into the infarct area. Thus, AS, SVD, and CAA are
related to infarcts, regardless of their nature. The under-
lying vessel disorder is, therefore, not predictive of the
ischemic (anemic) or hemorrhagic nature of an infarct.
On the other hand, the underlying vessel disorders have
influence on the infarct size. Large infarcts are bigger than
15–20 mm3. They are frequently ischemic (70–80%) and
due to thrombotic or embolic artery occlusion [73]. AS
plaque rupture with subsequent thrombosis and/or embolism
usually occurs in the extracranial parts of the vertebral and
the internal and common carotid arteries [73, 81]. Large
infarcts due cardiac embolism are less frequent [73, 81].
About 10% of all large infarcts are watershed infarcts. It is a
distinct type of infarct located between two vessel territories
that results from insufficient blood supply during hypoten-
sive episodes [52, 57, 157]. SVD and CAA usually do not
lead to large infarcts [73]. Therefore, large infarcts are
mainly linked to AS and its complications. Lacunar infarcts
are cavitating infarcts, measuring up to 5–15 mm3 in volume
or 5–10 mm in diameter [30, 44, 73, 102]. They are largely
confined to the cerebral white matter and subcortical struc-
tures, most commonly found in the putamen, caudate
nucleus, thalamus, pons, internal capsule and the cerebral
white matter. Lacunar infarcts are associated with SVD [17,
74] but not with CAA. Pathogenetically, hypertension, dia-
betes, previous brain infarcts, an increase of high-density
lipoproteins and triglycerides in the blood [36] were con-
sidered risk factors, but a recent review reported that this risk
is not greater than that for large infarcts [49]. However, SVD-
affected vessels showing lipohyalinosis or small vessel ath-
erosclerosis are often found in the center of lacunar infarcts
[30, 31, 111] presumably indicating that SVD is a major
cause of lacunar infarcts. The risk factors described for
lacunar infarcts are similar with those of AS and SVD. AS-
related or cardiac embolism can also cause lacunar infarcts
[33]. As opposed to large and lacunar infarcts, microinfarcts
are usually not visible at gross examination. They are smaller
than 5 mm in diameter. Multiple microinfarcts in the cortex
and the white matter rather than a single one likely impact
cognition [48]. Microinfarcts result either from AS-related
embolism, SVD, or CAA [14, 33, 53, 61, 99]. Due to the
location of the underlying vessel disorder, cortical microin-
farcts are often associated with CAA whereas subcortical
infarcts are mainly linked to SVD [7, 14, 53, 99, 118, 129,
132, 143].
In summary, AS is capable of causing infarcts of all size,
whereas SVD is only related to lacunar infarcts and micr-
oinfarcts and CAA is mainly restricted to microinfarcts.
These relationships can be easily explained by the vessel
types affected by the respective vessel disorders and do not
seem to reflect a more specific pathomechanism.
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Hemorrhages
Cerebral hemorrhages are blood extravasations into the
brain parenchyma larger than 10 mm in diameter and are
differentiated from microbleeds. Together with other dis-
orders, such as saccular aneurysms of the circle of Willis,
vascular malformations, or coagulation disorders, AS,
SVD, and CAA can lead to hemorrhage. In particular, AS
results in hemorrhage after rupture of an atherosclerotic
aneurysm [56], although this is a rare cause of intracerebral
hemorrhage. More often, SVD leads to intracerebral hem-
orrhage, especially when it is associated with arterial
hypertension. These hemorrhages preferentially occur after
rupture of the lenticulostriate artery [125, 153]. Lobar
hemorrhages with destruction of cortical tissue are fre-
quently associated with severe CAA [50, 79, 141, 143].
Microaneurysms can be formed in SVD- and CAA-affected
vessels (Fig. 3c) and are prone to rupture [87, 141, 142].
Microbleeds are blood extravasations into the perivascular
and/or Virchow-Robin space without further tissue dis-
placement and/or small intracerebral hemorrhages. They
usually measure less than 10 mm in diameter [44] and are
found in *6% of the population with an increasing ten-
dency during aging, especially in the presence of CAA [38,
63, 138]. Hemosiderin-laden macrophages within the
perivascular space indicate prior microbleeds [149].
Hypertension-related microbleeds are preferentially loca-
ted in the basal ganglia, thalamus, and the pons in
association with SVD-affected vessels [54]. Thus, SVD
and CAA are the major causes of cerebral hemorrhage and
microbleeds in the aged human brain, whereas AS com-
plications rarely lead to cerebral bleedings.
White matter lesions
White matter lesions, synonymous with leukoaraioses
when found in imaging examinations, are present in up to
65% of the subjects over 65 years of age. They are more
prevalent in patients with cerebrovascular disease or with
cardiovascular risk [58, 96]. Clinically, WMLs are often
asymptomatic [12, 25], but they can also impair cognition
[26, 105]. Leukoencephalopathy, Binswanger’s disease
(synonymous with subcortical arteriosclerotic encephalop-
athy), periventricular arteriosclerotic leukoencephalopathy,
and leukomalacia are clinical correlatives of WMLs [26,
48, 138]. Risk factors for the development of WMLs are
advanced age, female sex [114], increased plasma homo-
cysteine [47], increased ICAM levels [80], and arterial
hypertension [24]. Some of these risk factors such as
hypertension and increased plasma homocysteine levels
also act as risk factors for AS and SVD. WMLs usually
display, in variable degrees, white matter rarefaction (i.e.,
demyelination and axon loss), mild reactive astrocytosis,
edema, and macrophage reaction [28, 39, 48, 124]. These
changes are frequently observed in the frontal, parietal,
temporal, and occipital deep white matter, especially in the
centrum semiovale, and as a rule, spare the subcortical
U-fibers, which are located close to the border between the
cortex and the white matter [59, 98, 101, 113]. It is not
clear whether periventricular WMLs have the same nature
as those in the deep white matter [28]. White matter
infarcts, hemorrhages and enlarged perivascular spaces do
not fall into the category of WMLs [48]. SVD-affected
vessels are often seen together with perivascular WMLs
[140]. AS and CAA, on the other hand, are not directly
associated with WMLs because these vessel diseases are
usually not seen in white matter vessels. Pathogenetically,
SVD-related chronic hypoperfusion of the white matter and
BBB alterations are presumed to lead to the degeneration
of axons and myelin sheets, i.e. to WMLs [59, 98, 101, 136,
137, 140].
Pathogenetic relations between vessel disorders
and brain lesions
According to the issues discussed above, SVD can lead to
infarction, hemorrhage, and WMLs. In turn, infarction and
hemorrhage can be caused by AS, SVD, and CAA. Thus,
the type of brain lesion cannot be related to a specific
vessel disorder and vice versa. All vessel disorders result in
narrowing of the lumen of the affected blood vessels and
can lead to vessel occlusion with subsequent infarction.
Likewise, AS, SVD, and CAA damage the vessel wall.
Rupture with subsequent hemorrhage can take place.
In addition to these non-specific mechanisms, WMLs
and lacunar infarcts are mainly related to SVD. Despite
vessel occlusion leading to lacunar infarcts, chronic
hypoxia and SVD-related congestion of extracellular fluid
may contribute to the development of WMLs and lacunar
infarcts. This hypothesis is supported, first, by studies
showing that chronic hypoxia presumably causes WMLs
and lacunar infarcts given that oligodendrocytes are the
most vulnerable cell type under these conditions and that
their degeneration contributes to the development of
WMLs and lacunar infarcts [48, 82, 83, 101, 122, 152].
Thereby, chronic hypoxia may result from SVD-related
concentric fibrosis of the arterial walls and consecutive
hypoperfusion [30, 31, 111, 112, 140]. Second, SVD leads
to a leakage of plasma proteins, such as IgG, A2M and
apoE, into the enlarged perivascular spaces [139].
Recently, BBB alterations in patients with leukoaraiosis
(i.e. WMLs) and lacunar stroke have been described [136,
145]. Accordingly, these observations point to a SVD-
related alteration of the pre-capillary BBB segment
involved in the pathogenesis of WMLs and lacunar infarcts
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and, thereby, extend the present knowledge of SVD-related
BBB alterations and its association with vascular lesions
in addition to AD-related changes [127, 139]. Moreover,
it is well-known that plasma proteins leak into the brain
parenchyma of hypertensive or hypotensive animals [91,
137] and patients with vascular dementia [1]. Endothelial
changes have been found in animal models for hypo- as
well as hypertension [91, 92, 137] indicating that endo-
thelial cell alterations due to high arterial pressure or due to
chronic hypoxia in hypotensive states are capable of pro-
moting alterations of the pre-capillary BBB segment. In the
light of all these considerations, it is tempting to speculate
that chronic plasma protein leakage into the brain and
retention of extracellular fluid due to altered perivascular
clearance for the above-mentioned reasons contributes to
the development of WMLs and/or lacunar infarcts (Fig. 4b)
in addition to chronic hypoxia. Such a mechanism causing
alterations of tissue is well-known in liver and lung con-
gestion. Here, chronic hypoxia and a decreased venous
drainage of extracellular fluid and blood lead to a perive-
nous parenchymal necrosis with subsequent fibrosis [90].
In short, hemorrhage and infarction result from non-
specific vessel wall changes seen in AS, SVD, and CAA
whereas WMLs and lacunar infarcts appear to be specifi-
cally linked to SVD-related BBB leakage and chronic
hypoxia.
Conclusions
Despite the etiology of the vessel disorders, infarction and
hemorrhage appear to result non-specifically from vessel
wall changes of the respective vessel disorders. WMLs and
lacunar infarcts can be addressed quite specifically to SVD
[140]. The alteration of the pre-capillary segment of the
BBB, thereby, allows leakage of plasma proteins into the
vessel wall and into the perivascular space. These plasma
proteins may compete with the extracellular fluid of the
brain for perivascular drainage leading to retention of
extracellular fluid, including Ab in the brain. Such a
retention of Ab may also contribute to the development of
CAA and Alzheimer’s disease. ApoE is physiologically
involved in the perivascular clearance of the extracellular
fluid from brain. It is found in AS, SVD, and CAA lesions,
and may represent a link between these disorders. Taken
together, SVD-related alterations of the pre-capillary seg-
ment of the BBB seem to play an important role in vascular
pathology, i.e. WMLs, lacunar infarcts, and CAA.
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